Walgreens Needs New Treatment Options

Date : 03/04/2019 @ 09h03
Source : Dow Jones News
Valeur : Walgreens Boots Alliance Inc (WBA)
Cours : 51.45  -0.42 (-0.81%) @ 01h44
Walgreens Boots Alliance Cours Graphique
After Hours
Last Trade
Last $ 51,33 ▼ -0,12 (-0,23%)

Walgreens Needs New Treatment Options

Walgreens Boots Alliance (NASDAQ:WBA)
Graphique Historique de l'Action

1 an : De Fév 2019 à Fév 2020

Plus de graphiques de la Bourse Walgreens Boots Alliance
By WSJ City 

Pharmacy giant Walgreens Boots Alliance has a slumping business and an ailing stock price. That much became clear Tuesday after Walgreens announced fiscal second-quarter results, writes Charley Grant for Heard on the Street.


   -- The company said its profit fell 14% to $1.16bn in the most recent 
   -- Walgreens shares fell about 13% to $55.34 on Tuesday. 
   -- The stock is down 12% over the past year. 
   -- For 2019, Walgreens expects adjusted earnings per share at constant 
      currency rates to be roughly flat. 
   -- That's lower than its previous guidance for 7% to 12% growth. 

"This has been a disappointing quarter and I am equally disappointed that we have had to reduce our guidance. We will respond quickly to ensure we return to growth," said Walgreens Chief Executive Stefano Pessina, in a call with analysts.


The chain said it made less money on prescription drugs, which drive the bulk of store sales. That's because tougher economics around generics drove prices lower. Also driving prices lower: pressure from insurers to reduce reimbursements to pharmacies.

Comparable retail sales were down primarily due to a weak cough, cold and flu season, the company said. Also playing a role in the decline were a drop in seasonable merchandise sales and a shift away from sales of products like tobacco. "We are going to be more aggressive in our response to these rapidly shifting trends," Pessina said.


Identifying what went wrong is easier than fixing it. Walgreens increased its target for annual cost savings to more than $1.5bn by fiscal 2022, up from $1bn, but arresting the stock-price decline will likely require a more ambitious plan, because the US payer environment is unlikely to improve. After all, its largest competitor, CVS Health , now owns a major health insurer and should be better positioned to handle reimbursement pressures.

The competitive environment could worsen still. Amazon bought online pharmacy PillPack last summer and could conceivably expand its pharmacy presence in the years to come. On the bright side, Walgreens's balance sheet is in decent shape, and its strategy of pursuing partnerships means it could do a large deal if it chose. Walgreens could even mimic CVS and try to merge with a major health insurer.

A fuller story is available on WSJ.com

WSJ City: The news, the key facts and why it matters. Be deeply informed in less than five minutes. You can find more concise stories like this on the WSJ City app. Download now from the App Store or Google Play, or sign up to newsletters here http://www.wsj.com/newsletters?sub=356&mod=djemwsjcity


(END) Dow Jones Newswires

April 03, 2019 02:48 ET (06:48 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Dernières Valeurs Consultées
Société Gé..
CAC 40
Euro vs Do..
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.

Inscrivez-vous maintenant pour créer votre liste d'actions personnalisée, en streaming.

Les cours EURONEXT (CAC 40, etc. ) et FOREX (les devises) sont en direct si connecté.
NYSE, AMEX, et ASX sont en différé d'environ 20 minutes. Les autres cours sont en différé d'environ 15 minutes.

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

P: V:fr D:20200222 13:49:31